News

  Sequencing bone marrow DNA in paediatric and young adult patients with acute lymphoblastic leukaemia could help to predict those who will suffer a relapse after CAR‑T cell therapy, according to a new US study. The study was led by Dr Michael Pulsipher, from Pediatric Hematology and Oncology at Intermountain Primary Children’s Hospital and the Huntsman Cancer Institute of the University of Utah. The team found that in those who were treated with the CAR‑T cell therapy tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all who would eventually relapse. Other methods, including flow cytometry and monitoring recovery of B cell aplasia, were le...